Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Biotech M&A to Boom across a landscape of uncharted markets

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 11, 2023 10:10am

175 Views

Post# 35490504

RE:RE:RE:RE:Biotech M&A to Boom across a landscape of uncharted markets

Torreya Managing Director Tim Opler said a platform deal is coming — and soon. Also, Torreya's Opler says that immunology is hot — as evidenced by the Prometheus takeover.

When it comes to biotech M&A activity, cancer has been one of the hottest areas of focus. This is due in part to the significant progress that has been made in the development of cancer treatments in recent years. With new treatments showing promise in clinical trials and the potential for significant profits in the market, larger companies are looking to acquire young biotechs in the space.

One reason why cancer has been such a hot area of focus is the prevalence of the disease. Cancer affects millions of people worldwide and is a leading cause of death. As a result, there is a significant need for new and innovative treatments.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing